Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of YKYY032 injection in adults with hyperlipoproteinemia(a)
CTR20263950Phase 2Active
- Sponsor
- Yuekang Kechuang
- Start
- Oct 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of YKYY032 in hyperlipoproteinemia, sponsored by Yuekang Kechuang. Started Oct 2026; status: active.
02
Drugs
YKYY032
03
Conditions
hyperlipoproteinemia
Beyond the preview
Go deeper on CTR20263950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263950.